JO Volume 4 - Hepatitis - Clinical Care Options

Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.

Authors: Bajaj JS, Heuman DM, Wade JB, et al.

Citation: Gastroenterology. 2011;140:478-487.

Source: Journal Options for Hepatitis - Volume 4

Date Posted: 2/11/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.

Authors: Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ.

Citation: Aliment Pharmacol Ther. 2010;32:1323-1331.

Source: Journal Options for Hepatitis - Volume 4

Date Posted: 2/11/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.

Authors: de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al.

Citation: Gastroenterology. 2010;139:1934-1941.

Source: Journal Options for Hepatitis - Volume 4

Date Posted: 2/11/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

Authors: Marcellin P, Forns X, Goeser T, et al.

Citation: Gastroenterology. 2011;140:459-468.

Source: Journal Options for Hepatitis - Volume 4

Date Posted: 2/11/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.

Authors: Moucari R, Forestier N, Larrey D, et al.

Citation: Gut. 2010;59:1694-1698.

Source: Journal Options for Hepatitis - Volume 4

Date Posted: 2/11/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.

Authors: Patterson SJ, George J, Strasser SI, et al.

Citation: Gut. 2011;60:247-254.

Source: Journal Options for Hepatitis - Volume 4

Date Posted: 2/11/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.

Authors: Reijnders JG, Rijckborst V, Sonneveld MJ, et al.

Citation: J Hepatol. 2010;[Epub ahead of print].

Source: Journal Options for Hepatitis - Volume 4

Date Posted: 2/11/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

Authors: Williams CD, Stengel J, Asike MI, et al.

Citation: Gastroenterology. 2011;140:124-131.

Source: Journal Options for Hepatitis - Volume 4

Date Posted: 2/11/2011

Capsule Summary | Expert Commentary | Slideset | Abstract
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.

Authors: Berg T, Marcellin P, Zoulim F, et al.

Citation: Gastroenterology. 2010;139:1207-1217.

Source: Journal Options for Hepatitis - Volume 4

Date Posted: 10/18/2010

Capsule Summary | Expert Commentary | Slideset | Abstract
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

Authors: Chang TT, Liaw YF, Wu SS, et al.

Citation: Hepatology. 2010;52:886-893.

Source: Journal Options for Hepatitis - Volume 4

Date Posted: 10/18/2010

Capsule Summary | Expert Commentary | Slideset | Abstract

Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

Other Sites

Topics

Educational Formats

Program Resources

User Resources

Video

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Journal Options for Hepatitis - Volume 4 Source: Journal Options for Hepatitis - Volume 4
Table of Contents Issue 1 Collection • Issue 1 Collection Issue 2 Collection • Issue 2 Collection Issue 3 Collection • Issue 3 Collection Articles	Journal Options Volume Overview Journal Options for Hepatitis - Volume 4 Review expert faculty member commentaries on the most clinically relevant new hepatology journal articles. Latest Content 10 of 24 Shown Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Authors: Bajaj JS, Heuman DM, Wade JB, et al. Citation: Gastroenterology. 2011;140:478-487. Source: Journal Options for Hepatitis - Volume 4 Date Posted: 2/11/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Authors: Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Citation: Aliment Pharmacol Ther. 2010;32:1323-1331. Source: Journal Options for Hepatitis - Volume 4 Date Posted: 2/11/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Authors: de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Citation: Gastroenterology. 2010;139:1934-1941. Source: Journal Options for Hepatitis - Volume 4 Date Posted: 2/11/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Authors: Marcellin P, Forns X, Goeser T, et al. Citation: Gastroenterology. 2011;140:459-468. Source: Journal Options for Hepatitis - Volume 4 Date Posted: 2/11/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Authors: Moucari R, Forestier N, Larrey D, et al. Citation: Gut. 2010;59:1694-1698. Source: Journal Options for Hepatitis - Volume 4 Date Posted: 2/11/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Authors: Patterson SJ, George J, Strasser SI, et al. Citation: Gut. 2011;60:247-254. Source: Journal Options for Hepatitis - Volume 4 Date Posted: 2/11/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. Authors: Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Citation: J Hepatol. 2010;[Epub ahead of print]. Source: Journal Options for Hepatitis - Volume 4 Date Posted: 2/11/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Authors: Williams CD, Stengel J, Asike MI, et al. Citation: Gastroenterology. 2011;140:124-131. Source: Journal Options for Hepatitis - Volume 4 Date Posted: 2/11/2011 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Authors: Berg T, Marcellin P, Zoulim F, et al. Citation: Gastroenterology. 2010;139:1207-1217. Source: Journal Options for Hepatitis - Volume 4 Date Posted: 10/18/2010 Capsule Summary \| Expert Commentary \| Slideset \| Abstract Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Authors: Chang TT, Liaw YF, Wu SS, et al. Citation: Hepatology. 2010;52:886-893. Source: Journal Options for Hepatitis - Volume 4 Date Posted: 10/18/2010 Capsule Summary \| Expert Commentary \| Slideset \| Abstract 10 of 24 Shown Show 10 More Loading...	Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. Contact Info Educational grants provided by: Educational grants support only the CME-certified components of this program.

Source: Journal Options for Hepatitis - Volume 4

Table of Contents

Latest Content